BRPI0409497A - métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite - Google Patents

métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite

Info

Publication number
BRPI0409497A
BRPI0409497A BRPI0409497-2A BRPI0409497A BRPI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A
Authority
BR
Brazil
Prior art keywords
methods
diagnosis
treatment
tyrosine kinases
relates
Prior art date
Application number
BRPI0409497-2A
Other languages
English (en)
Inventor
Sherif Daouti
Brian Jude Latario
Chandrika Saidapet Kumar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409497A publication Critical patent/BRPI0409497A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"MéTODOS E COMPOSIçõES QUE ALVEJAM TIROSINA CINASES PARA A DIAGNOSE E TRATAMENTO DE OSTEOARTRITE". A presente invenção refere-se aos membros de uma subfamília de receptor tirosina cinases compreendendo TYRO3, Axl, cMer e ligantes dos mesmos, como GAS6 que são alvos adequados para o desenvolvimento de novas terapias para tratar, impedir ou melhorar OA. A invenção também refere-se aos métodos para tratar e/ou melhorar OA e composições farmacêuticas dos mesmos compreendendo moduladores com efeito inibidor na expressão ou atividade dos membros da mesma subfamília de receptores tirosina e ligantes relacionados. A invenção também refere-se a um método para identificar compostos com utilidade terapêutica para tratar OA, compreendendo identificar compostos que podem, por exemplo, inibir a atividade e/ou expressão dos mesmos polipeptídeos.
BRPI0409497-2A 2003-04-18 2004-04-16 métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite BRPI0409497A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46393503P 2003-04-18 2003-04-18
PCT/EP2004/004052 WO2004092735A2 (en) 2003-04-18 2004-04-16 Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
BRPI0409497A true BRPI0409497A (pt) 2006-05-02

Family

ID=33300099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409497-2A BRPI0409497A (pt) 2003-04-18 2004-04-16 métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite

Country Status (9)

Country Link
US (1) US20070142273A1 (pt)
EP (1) EP1618385A2 (pt)
JP (1) JP2006524496A (pt)
CN (1) CN1774634A (pt)
AU (2) AU2004231036A1 (pt)
BR (1) BRPI0409497A (pt)
CA (1) CA2522984A1 (pt)
MX (1) MXPA05011171A (pt)
WO (1) WO2004092735A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102456A1 (en) 2004-03-27 2005-11-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
CA2703519C (en) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
WO2010115841A1 (en) * 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
KR20200100866A (ko) * 2010-01-22 2020-08-26 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-전이성 요법에서 ａｘｌ 신호전달의 저해
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
CA2894539C (en) 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
MX2015011873A (es) * 2013-03-15 2016-01-25 Bayer Healthcare Llc Dominios gla como agentes de direccionamiento.
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230614T2 (de) * 1991-07-02 2000-06-21 Scripps Research Inst La Jolla Protein-s polypeptide und deren verwendungen
EP0706564A1 (en) * 1993-06-30 1996-04-17 Rijksuniversiteit Leiden Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods
JPH09506250A (ja) * 1993-11-23 1997-06-24 ジェネンテク，インコーポレイテッド Ｒｓｅと命名される蛋白チロシンキナーゼ
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
AU2003276958A1 (en) * 2002-09-24 2004-04-19 Centocor, Inc. Epitope-tagged recombinant growth arrest specific gene 6 protein

Also Published As

Publication number Publication date
WO2004092735A3 (en) 2005-03-17
WO2004092735A2 (en) 2004-10-28
MXPA05011171A (es) 2005-12-14
CN1774634A (zh) 2006-05-17
US20070142273A1 (en) 2007-06-21
JP2006524496A (ja) 2006-11-02
AU2004231036A1 (en) 2004-10-28
CA2522984A1 (en) 2004-10-28
EP1618385A2 (en) 2006-01-25
AU2008202807A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
BR112021017430A2 (pt) Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos
Vaillancourt et al. Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis
BRPI0409497A (pt) métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
Kim et al. LIM kinase-2 induces programmed necrotic neuronal death via dysfunction of DRP1-mediated mitochondrial fission
Lin et al. Dual regulation of microglia and neurons by Astragaloside IV‐mediated mTORC1 suppression promotes functional recovery after acute spinal cord injury
BRPI0622054B8 (pt) composto e composição farmacêutica
Chen et al. Musashi-1 promotes chemoresistant granule formation by PKR/eIF2α signalling cascade in refractory glioblastoma
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BRPI0406834A (pt) Tratamento de doença com agonistas totais do receptor nach alfa-7
Cortese et al. Carnosic acid induces proteasomal degradation of Cyclin B1, RB and SOX2 along with cell growth arrest and apoptosis in GBM cells
Nilsson et al. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells
Bareford et al. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
Sun et al. Aluminum trichloride induces bone impairment through TGF-β1/Smad signaling pathway
Lee et al. Cytoprotective effect of eriodictyol in UV-irradiated keratinocytes via phosphatase-dependent modulation of both the p38 MAPK and Akt signaling pathways
Yan et al. Effect of calcitonin gene‐related peptide on nitric oxide production in osteoblasts: an experimental study
Wang et al. Arbutin suppresses osteosarcoma progression via miR‐338‐3p/MTHFD1L and inactivation of the AKT/mTOR pathway
Singhatanadgit et al. Geranylgeraniol prevents zoledronic acid-mediated reduction of viable mesenchymal stem cells via induction of Rho-dependent YAP activation
Smythe et al. Altered caveolin-3 expression disrupts PI (3) kinase signaling leading to death of cultured muscle cells
Cirak et al. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone‐refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A
Lee et al. Rosa hybrida extract suppresses vascular smooth muscle cell responses by the targeting of signaling pathways, cell cycle regulation and matrix metalloproteinase-9 expression
Zhang et al. Pim‐1 kinase as activator of the cell cycle pathway in neuronal death induced by DNA damage
Zhu et al. Radiotherapy suppresses bone cancer pain through inhibiting activation of cAMP signaling in rat dorsal root ganglion and spinal cord
Xiang et al. Nuclear factor erythroid 2-related factor 2 antibody attenuates thermal hyperalgesia in the dorsal root ganglion: Neurochemical changes and behavioral studies after sciatic nerve-pinch injury

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.